Verastem Inc

The KRAS inhibitor market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, according to DelveInsight, with the United States expected to account for nearly 70% of the total. Roots Analysis sizes the category differently, projecting the global KRAS market will grow from approximately $557 million in 2025 to approximately $3.98 billion by 2035, a CAGR of about 21%, and expects intravenously administered therapies to grow faster than the oral drugs that dominate the category today. KRAS mutations account for approximately 85% of RAS-associated cancers in humans, including about 90% of pancreatic cancers, according to Eli Lilly and Company, while in colorectal cancer KRAS mutations appear in approximately 40% of all cases, according to Amgen, yet the G12C subtype targeted by the first approved inhibitors is present in only about 3% to 5% of colorectal cancers. The clinical bar moved sharply in April 2026, when a Phase 3 trial of an oral RAS(ON) multi-selective inhibitor in previously treated metastatic pancreatic cancer reported a median overall survival of 13.2 months versus 6.7 months for chemotherapy, according to the sponsor's SEC filing. Oncolytics Biotech announced positive preclinical results on September 10, 2026 from a study evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model, reporting that pelareorep activity was maintained alongside RAS inhibition without evidence of antagonism, though the company said the incremental activity associated with pelareorep became less evident after a transition to less frequent weekly dosing. Oncolytics also said it received written FDA feedback on August 18, 2026 on the design of a potential pivotal Part B expansion of its ongoing REO 033 study in second-line RAS-mutant, microsatellite stable metastatic colorectal cancer, with objective response rate potentially supporting accelerated approval and progression-free survival potentially supporting full approval; the ongoing Part A enrolls 60 patients. Revolution Medicines announced the FDA accepted for review its New Drug Application for daraxonrasib, an oral RAS(ON) multi-selective inhibitor, for previously treated metastatic pancreatic ductal adenocarcinoma, supported by the Phase 3 RASolute 302 trial in which daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months for chemotherapy with a hazard ratio of 0.40. Amgen reported LUMAKRAS/LUMYKRAS sales up 23% year-over-year to $111 million in its second quarter 2026 results, while total revenues rose 10% to $10.1 billion, and Eli Lilly announced the FDA granted Breakthrough Therapy designation to olomorasib as a monotherapy for adults with advanced pancreatic cancer with a KRAS G12C mutation. Verastem Oncology said it will host an investor event on October 14, 2026 to present initial efficacy and updated safety and tolerability data for VS-7375, its investigational oral KRAS G12D inhibitor, and reported second quarter 2026 net product revenue of $25.1 million for AVMAPKI FAKZYNJA CO-PACK.